1. **NAME OF THE MEDICINAL PRODUCT**

Yondelis 0.25 mg powder for concentrate for solution for infusion.

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each vial contains 0.25 mg of trabectedin.

1 ml of reconstituted solution contains 0.05 mg of trabectedin.

**Excipients:**

Each vial contains 2 mg of potassium and 0.1 g of sucrose.

For a full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Powder for concentrate for solution for infusion.

White to off-white powder.

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**

Yondelis is indicated for the treatment of patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.

4.2 **Posology and method of administration**

Yondelis must be administered under the supervision of a physician experienced in the use of chemotherapy. Its use should be confined to qualified oncologists or other health professionals specialised in the administration of cytotoxic agents.

The recommended dose is 1.5 mg/m² body surface area, administered as an intravenous infusion over 24 hours with a three-week interval between cycles. Administration through a central venous line is strongly recommended (see section 6.6).

All patients must receive 20 mg of dexamethasone intravenously 30 minutes prior to Yondelis; not only as anti-emetic prophylaxis, but also because it appears to provide hepatoprotective effects. Additional anti-emetics may be administered as needed.

The following criteria are required to allow treatment with Yondelis:

- Absolute neutrophil count (ANC) ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Bilirubin ≤ upper limit of normal (ULN)
- Alkaline phosphatase ≤ 2.5 ULN (consider hepatic isoenzymes 5-nucleotidase or GGT, if the elevation could be osseous in origin).
- Albumin ≥ 25 g/l.
- Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤ 2.5 x ULN
- Creatinine clearance ≥ 30 ml/min
- Creatine phosphokinase (CPK) ≤ 2.5 ULN
- Haemoglobin ≥ 9 g/dl

The same criteria as above must be met prior to re-treatment. Otherwise treatment must be delayed for up to 3 weeks until the criteria are met.

Additional monitoring of haematological parameters bilirubin, alkaline phosphatase, aminotransferases and CPK should occur weekly during the first two cycles of therapy, and at least once between treatments in subsequent cycles.

The same dose should be given for all cycles provided that no grade 3-4 toxicities are seen and that the patient fulfils the re-treatment criteria.

**Dose adjustments during treatment**

Prior to re-treatment, patients must fulfil the baseline criteria defined above. If any of the following events occur at any time between cycles, the dose must be reduced to 1.2 mg/m² for subsequent cycles:

- Neutropenia < 500/mm³ lasting for more than 5 days or associated with fever or infection
- Thrombocytopenia < 25,000/mm³
- Increase of bilirubin > ULN and/or alkaline phosphatase > 2.5 x ULN
- Increase of aminotransferases (AST or ALT) > 2.5 x ULN which has not recovered by day 21
- Any other grade 3 or 4 adverse reactions (such as nausea, vomiting, fatigue)

Once a dose has been reduced because of toxicity, dose escalation in the subsequent cycles is not recommended. If any of these toxicities reappear in subsequent cycles in a patient exhibiting clinical benefit, the dose may be further reduced to 1 mg/m². In the event that further dose reductions are necessary, treatment discontinuation should be considered.

**Duration of treatment**

In clinical trials, there were no pre-defined limits to the number of cycles administered. Treatment continued whilst clinical benefit was noted. Trabectedin has been administered for 6 or more cycles in 168 out of 569 (29.5%) patients treated with the proposed dose and schedule. This regime has been used for up to 38 cycles. No cumulative toxicities have been observed in patients treated with multiple cycles.

**Special patient populations**

*Paediatric patients*

The safety and efficacy of trabectedin in paediatric patients have not yet been established. Therefore, this medicinal product must not be used in children and adolescents until further data become available.

*Elderly patients*

No specific studies in elderly patients have been performed. Overall 20% of the 1164 patients in the integrated safety analysis were over 65 years. No relevant differences in the safety profile were seen in this patient population. It seems that plasma clearance and distribution volume of trabectedin are not influenced by age. Therefore, dose adjustments based uniquely on age criteria are not routinely recommended.
Patients with impaired hepatic function

No studies with the proposed regime have been conducted in patients with liver dysfunction. Thus, data are not available to recommend a lower starting dose in patients with hepatic impairment. However, special caution is advised and dose adjustments may be necessary in these patients since systemic exposure is probably increased and the risk of hepatotoxicity might be increased. Patients with elevated bilirubin must not be treated with Yondelis (see section 4.4).

Patients with impaired renal function

Studies including patients with severe renal insufficiency (creatinine clearance < 30 ml/min) have not been conducted and therefore Yondelis must not be used in this patient population (see section 4.4). Considering the pharmacokinetic characteristics of trabectedin (see section 5.2), no dose adjustments are warranted in patients with mild or moderate renal impairment.

For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.

4.3 Contraindications

- Hypersensitivity to trabectedin or to any of the excipients
- Concurrent serious or uncontrolled infection
- Breast-feeding (see section 4.6)
- Combination with yellow fever vaccine (see section 4.4)

4.4 Special warnings and precautions for use

Hepatic impairment

Patients must meet specific criteria on hepatic function parameters to start treatment with Yondelis. Since systemic exposure to trabectedin is probably increased due to hepatic impairment and therefore the risk of hepatotoxicity might be increased, patients with clinically relevant liver diseases, such as active chronic hepatitis, must be closely monitored and the dose adjusted if needed. Patients with elevated bilirubin must not be treated with trabectedin (see section 4.2).

Renal impairment

Creatinine clearance must be monitored prior to and during treatment. Trabectedin must not be used in patients with creatinine clearance < 30 ml/min (see section 4.2).

Neutropenia and thrombocytopenia

Grades 3 or 4 neutropenia and thrombocytopenia associated with trabectedin therapy have been very commonly reported. A full blood cell count including differential and platelet count must be performed at baseline, weekly for the first two cycles and then once between cycles (see section 4.2). Patients who develop fever should promptly seek medical attention. If this occurs, active supportive therapy should be started immediately.

Nausea and vomiting

Anti-emetic prophylaxis with dexamethasone must be administered to all patients (see section 4.2).

Rhabdomyolysis and severe CPK elevations (> 10 x ULN)

Trabectedin must not be used in patients with CPK > 2.5 ULN (see section 4.2). Rhabdomyolysis has been uncommonly reported, usually in association with myelotoxicity, severe liver function test abnormalities and/or renal failure. Therefore, CPK should be closely monitored whenever a patient
may be experiencing any of these toxicities. If rhabdomyolysis occurs, supportive measures such as parenteral hydration, urine alkalinisation and dialysis should be promptly established, as indicated. Treatment with Yondelis should be discontinued until the patient fully recovers.

Caution should be taken if medicinal products associated with rhabdomyolysis (e.g. statins), are administered concomitantly with trabectedin, since the risk of rhabdomyolysis may be increased

Liver Function Test (LFT) abnormalities

Reversible acute increases in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) have been reported in most patients. Yondelis must not be used in patients with elevated bilirubin. Patients with increases in AST, ALT and alkaline phosphatase between cycles may necessitate dose reduction (see section 4.2).

Injection site reactions

The use of central venous access is strongly recommended (see section 4.2). Patients may develop a potentially severe injection site reaction when trabectedin is administered through a peripheral venous line.

Others

Co-administration of Yondelis with potent inhibitors of the enzyme CYP3A4 should be avoided (see section 4.5). If this is not possible, close monitoring of toxicities are required and dose reductions of trabectedin should be considered.

Caution should be taken if medicinal products associated with hepatotoxicity are administered concomitantly with trabectedin, since the risk of hepatotoxicity may be increased.

Concomitant use of trabectedin with phenytoin may reduce phenytoin absorption leading to an exacerbation of convulsions. Combination of trabectedin with phenytoin or live attenuated vaccines is not recommended and with yellow fever vaccine is specifically contraindicated (see sections 4.3 and 4.5).

The concomitant use of trabectedin with alcohol must be avoided (see section 4.5).

Men in fertile age and women of childbearing potential must use effective contraception during treatment and 3 months thereafter for women and immediately inform the treating physician if a pregnancy occurs, and 5 months after treatment for men (see section 4.6).

This medicine contains potassium, less than 1 mmol (39 mg) per vial, i.e. essentially “potassium-free”.

4.5 Interaction with other medicinal products and other forms of interaction

Effects of other substances on trabectedin

In vivo interaction studies have not been performed. Since trabectedin is metabolised mainly by CYP3A4, co-administration of substances that inhibit this isoenzyme e.g. ketoconazole, fluconazole ritonavir or clarithromycin could decrease metabolism and increase trabectedin concentrations. If such combinations are needed, close monitoring of toxicities is required (see section 4.4). Likewise co-administration with potent inducers of this enzyme (e.g. rifampicin, phenobarbital, Saint John’s Wort) may decrease the systemic exposure to trabectedin.

Alcohol consumption must be avoided during treatment with trabectedin due to the hepatotoxicity of the medicinal product (see section 4.4).
Preclinical data have demonstrated that trabectedin is a substrate to P-gp. Concomitant administration of inhibitors of Pgp, e.g. cyclosporine and verapamil, may alter trabectedin distribution and/or elimination. The relevance of this interaction e.g. CNS toxicity has not been established. Caution should be taken in such situations.

4.6 Pregnancy and lactation

Pregnancy

No sufficient clinical data on exposed pregnancies are available. However, based on its known mechanism of action, trabectedin may cause serious birth defects when administered during pregnancy. Trabectedin should not be used during pregnancy unless clearly necessary. If it is used during pregnancy, the patient must be informed of the potential risk to the foetus (see section 5.3) and be monitored carefully. If trabectedin is used at the end of pregnancy, potential adverse reactions should be monitored carefully in the newborns.

Fertility

Men in fertile age and women of childbearing potential must use effective contraception during treatment and 3 months thereafter for women and immediately inform the treating physician if a pregnancy occurs (see section 5.3) and 5 months after treatment for men (see section 4.4).

Trabectedin can have genotoxic effects. Advice on conservation of sperm should be sought prior to treatment because of the possibility of irreversible infertility due to therapy with Yondelis. If pregnancy occurs during treatment the possibility of genetic counselling should be considered. Genetic counselling is also recommended for patients wishing to have children after therapy.

Lactation

It is not known whether trabectedin is excreted in human milk. The excretion of trabectedin in milk has not been studied in animals. Breast-feeding is contraindicated during treatment and 3 months thereafter (see section 4.3).

4.7 Effects on ability to drive and use machines

No studies on the effects of the ability to drive and to use machines have been performed. However, fatigue and/or asthenia have been reported in patients receiving trabectedin. Patients who experience any of these events during therapy must not drive or operate machines.

4.8 Undesirable effects

Unless otherwise specified, the following safety profile of Yondelis is based on the evaluation in clinical trials of 569 patients treated up to April 2007 with the recommended treatment regime in several cancer types including soft tissue sarcoma, breast cancer, osteosarcoma, ovarian cancer, GIST, melanoma and renal carcinoma.

Approximately 91% of patients can be expected to have adverse reactions of any grade. Around 40% of patients are expected to have adverse reactions of grade 3 or 4 severity. The most common adverse reactions of any severity grade were nausea, fatigue, vomiting, anorexia, neutropenia, and increases in AST/ALT.
Fatal adverse reactions have occurred in 1.9% of patients. They were often the result of a combination of events including pancytopenia, febrile neutropenia, some of them with sepsis, hepatic involvement, renal failure and rhabdomyolysis.

**Adverse reactions**

The frequencies of the adverse reactions reported below are classified as very common (≥ 1/10), common (≥ 1/100 to < 1/10) and uncommon (≥ 1/1000 to < 1/100).

The table below displays the adverse reactions reported in ≥ 1% of patients according to the standard MedDRA system organ class. Both adverse events and laboratory values have been used to provide frequencies. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Adverse reactions reported in ≥ 1% of patients in clinical trials at the recommended regime [1.5 mg/m², 24 hour infusion every 3 weeks (24-h q3wk)]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investigations</td>
<td><strong>Very Common</strong> Blood creatine phosphokinase increased, Blood creatinine increased, Blood albumin decreased</td>
</tr>
<tr>
<td></td>
<td><strong>Common</strong> Weight decreased</td>
</tr>
<tr>
<td>Blood and</td>
<td><strong>Very Common</strong> Neutropenia, Thrombocytopenia, Anaemia, Leukopenia</td>
</tr>
<tr>
<td>Lymphatic System</td>
<td><strong>Common</strong> Febrile neutropenia</td>
</tr>
<tr>
<td>Disorders</td>
<td></td>
</tr>
<tr>
<td>Nervous System</td>
<td><strong>Very Common</strong> Headache</td>
</tr>
<tr>
<td>Disorders</td>
<td><strong>Common</strong> Peripheral sensory neuropathy, Dysgeusia, Dizziness, Paraesthesia</td>
</tr>
<tr>
<td>Respiratory,</td>
<td><strong>Common</strong> Dyspnoea, Cough</td>
</tr>
<tr>
<td>Thoracic and</td>
<td></td>
</tr>
<tr>
<td>Mediastinal</td>
<td></td>
</tr>
<tr>
<td>Disorders</td>
<td><strong>Common</strong> Diarrhoea, Stomatitis, Abdominal pain, Dyspepsia, Upper abdominal pain</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td><strong>Very Common</strong> Vomiting , Nausea, Constipation</td>
</tr>
<tr>
<td>disorders</td>
<td><strong>Common</strong> Diarrhoea , Stomatitis, Abdominal pain, Dyspepsia, Upper abdominal pain</td>
</tr>
<tr>
<td>Skin and Subcutaneous Tissue Disorders</td>
<td><strong>Common</strong> Alopecia</td>
</tr>
<tr>
<td>Musculoskeletal and Connective Tissue Disorders</td>
<td><strong>Common</strong> Myalgia, Arthralgia, Back pain</td>
</tr>
<tr>
<td>Metabolism and Nutrition Disorders</td>
<td><strong>Very Common</strong> Anorexia</td>
</tr>
<tr>
<td>Infections and Infestations</td>
<td><strong>Common</strong> Dehydration, Decreased appetite, Hypokalaemia</td>
</tr>
<tr>
<td>Vascular Disorders</td>
<td><strong>Common</strong> Infection</td>
</tr>
<tr>
<td>General Disorders and Administration Site Conditions</td>
<td><strong>Very Common</strong> Fatigue, Asthenia</td>
</tr>
<tr>
<td></td>
<td><strong>Common</strong> Pyrexia, Oedema, Oedema peripheral, Injection site reaction</td>
</tr>
</tbody>
</table>
Hepatobiliary Disorders Very Common
Hyperbilirubinemia, Alanine aminotransferase increased, Aspartate aminotransferase increased, Blood alkaline phosphatase increased, Gamma-glutamyltransferase increased

Psychiatric Disorders Common
Insomnia

Most frequent adverse reactions

Blood and Lymphatic system disorders

**Neutropenia:** Neutropenia occurred in 77% of patients. Grade 3 and 4 neutropenia occurred in 26% and 24% of patients respectively. The analysis per cycle showed that neutropenia of grade 3 and 4 occurred in approximately 19% and 8% of cycles respectively. Febrile neutropenia occurred in 2% of patients and in < 1% of cycles.

Neutropenia followed a predictable pattern of rapid onset and reversibility, and was rarely associated with fever or infection.

**Thrombocytopenia:** Grade 3 and 4 thrombocytopenia occurred in 11% and 2% of patients respectively. The analysis per cycle showed that thrombocytopenia of grade 3 and 4 occurred in approximately 3% and < 1% of cycles respectively. Bleeding events associated to thrombocytopenia occurred in < 1% of patients.

**Anaemia:** Anaemia occurred in 93% of patients although 46% of patients were anaemic at baseline. Grade 3 and 4 anaemia occurred in 10% and 3% of patients respectively. The analysis per cycle showed that anaemia of grade 3 and 4 occurred in approximately 3% and 1% of cycles respectively.

Hepatobiliary disorders

**AST/ALT increases:** Transient grade 3 increases of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were observed in 38% and 44% of the patients and grade 4 elevations in 3% and 7% of the patients, respectively. The median time to reach the peak values was 5 days for both AST and ALT. Most of the values had decreased to grade 1 or resolved by day 14-15 (see section 4.4). Grade 3 elevations of AST and ALT occurred in 12% and 20% of cycles respectively. Grade 4 elevations of AST and ALT occurred in 1% and 2% of cycles respectively. Most transaminase elevations improved to grade 1 or to pre-retreatment levels within 15 days, and less than 2% of cycles had recovering times longer than 25 days. ALT and AST increases did not follow a cumulative pattern but showed a tendency towards less severe elevations over time.

**Hyperbilirubinemia:** Grades 1 to 2 bilirubin increases were observed in 23% of the patients. Grade 3 hyperbilirubinemia occurred in 1% of patients. Bilirubin peaks approximately a week after onset and resolves approximately two weeks after onset.

Clinical manifestations of severe hepatic injury were uncommon with a lower than 1% incidence of individual signs and symptoms including jaundice, hepatomegaly or liver pain. Mortality in the presence of hepatic injury occurred in less than 1% of patients.

Other adverse reactions

**Nausea, vomiting, diarrhoea and constipation:** Nausea and vomiting were reported in 63 and 38.5% of patients respectively. Grade 3-4 nausea and vomiting were reported in 6% and 6.5% of patients, respectively. Grade 3-4 diarrhoea and constipation were reported in less than 1% of patients.
Stomatitis: Grade 3-4 mucositis was reported in less than 1% of the patients.

Fatigue/Asthenia: Grade 3-4 fatigue/asthenia occurred in 9 and 1% of patients respectively.

Anorexia: Grade 3-4 anorexia occurred in less than 1% of the patients.

CPK elevations and rhabdomyolysis: CPK elevations of any grade were observed in 26% of patients. Grade 3 or 4 increases of CPK were observed in 4% of patients. CPK increases in association with rhabdomyolysis were reported in less than 1% of patients.

Dyspnoea: Grade 3-4 dyspnoea reported as trabectedin related occurred in 2% of the patients.

Alopecia: Alopecia was reported in approximately 3% of all patients, of which the majority was grade 1 alopecia.

4.9 Overdose

There is limited data on the effects of trabectedin overdose. The major anticipated toxicities are gastrointestinal, bone marrow suppression and hepatic toxicity. There is no specific antidote for trabectedin currently available. In the event of an overdose, patients should be closely monitored and symptomatic supportive care measures instituted as required.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agent, ATC code: L01CX01.

Mechanism of action

Trabectedin binds to the minor groove of DNA, bending the helix to the major groove. This binding to DNA triggers a cascade of events affecting several transcription factors, DNA binding proteins, and DNA repair pathways, resulting in perturbation of the cell cycle. Trabectedin has been shown to exert antiproliferative in vitro and in vivo activity against a range of human tumour cell lines and experimental tumours, including malignancies such as sarcoma, breast, non-small cell lung, ovarian and melanoma.

Clinical efficacy

The efficacy and safety of trabectedin is based in a randomised trial in patients with locally advanced or metastatic liposarcoma or leiomyosarcoma, whose disease had progressed or relapsed after treatment with at least anthracyclines and ifosfamide. In this trial trabectedin was administered either at 1.5 mg/m² as a 24-hour intravenous infusion every 3 weeks or at 0.58 mg/m² weekly as a 3-hour intravenous infusion for 3-weeks of a 4-week cycle. The protocol specified final time to progression (TTP) analysis showed a 26.6% reduction in the relative risk of progression for patients treated in the 24-h q3wk group (Hazard Ratio = 0.734 CI 0.554-0.974). Median TTP values were 3.7 months (CI: 2.1-5.4 m) in the 24-h q3wk group and 2.3 months (CI: 2.0-3.5 m) in the 3-h qwk group (p=0.0302). No significant differences were detected in overall survival (OS). Median OS with the 24-h q3wk regime was 13.9 months (CI: 12.5-18.6) and 60.2% of patients were alive at 1 year (CI: 52.0-68.5%).

Additional efficacy data are available from 3 single-arm Phase II trials with similar populations treated with the same regime. These trials evaluated a total of 100 patients with lipo and leiomyosarcoma and 83 patients with other types of sarcoma.
This medicinal product has been authorised under “Exceptional Circumstances”. This means that due to the rarity of the disease it has not been possible to obtain complete information on this medicinal product.

The European Medicines Agency (EMEA) will review any new information which may become available every year and this SPC will be updated as necessary.

5.2 Pharmacokinetic properties

Systemic exposure after administration as a 24 hour constant rate intravenous infusion is dose proportional at doses up to and including 1.8 mg/m². Trabectedin pharmacokinetic profile is consistent with a multiple-compartment disposition model.

Following intravenous administration, trabectedin demonstrates a high apparent volume of distribution, consistent with extensive tissue and plasma protein binding (94 to 98% of trabectedin in plasma is protein bound). The distribution volume at steady state of trabectedin in human subjects exceeds 5000 l.

Cytochrome P450 3A4 is the major cytochrome P450 isozyme responsible for the oxidative metabolism of trabectedin at clinically relevant concentrations. Other P450 enzymes may contribute to metabolism. Trabectedin does not induce or inhibit major cytochrome P450 enzymes.

Renal elimination of unchanged trabectedin in humans is low (less than 1%). The terminal half-life is long (population value of the terminal elimination phase: 180-hr). After a dose of radiolabelled trabectedin administered to cancer patients, faecal mean (SD) recovery of total radioactivity is 58% (17%), and urinary mean (SD) recovery is 5.8% (1.73%). Based on the population estimate for plasma clearance of trabectedin (31.5 l/h) and blood/plasma ratio (0.89), the clearance of trabectedin in whole blood is approximately 35 l/h. This value is approximately one-half the rate of human hepatic blood flow. Thus the trabectedin extraction ratio can be considered moderate. The inter-patient variability of the population estimate for plasma clearance of trabectedin was 51% and intra-patient variability was 28%.

Special populations

A population pharmacokinetic analysis indicated that the plasma clearance of trabectedin is not influenced by age (range 19-83 years), or gender. The effects of race and ethnicity on trabectedin pharmacokinetics have not been studied.

Impaired renal function

There is no relevant influence of renal function measured by creatinine clearance on trabectedin pharmacokinetics within the range of values (≥ 34.4 ml/min) present in the patients included in the clinical studies. No data are available in patients with a creatinine clearance of less than 34.4 ml/min. The low recovery (< 9% in all studied patients) of total radioactivity in the urine after a single dose of 14C-labelled trabectedin indicates that renal impairment has little influence on the elimination of trabectedin or its metabolites.

Impaired hepatic function

Although the population analysis showed no relationship between the serum liver enzymes concentrations and the plasma clearance of trabectedin, systemic exposure to trabectedin may be increased in patients with hepatic impairment; therefore close monitoring of toxicity is warranted.
5.3 Preclinical safety data

Preclinical data indicate that trabectedin has limited effect on the cardiovascular, respiratory and central nervous system at exposures below the therapeutic clinical range, in terms of AUC.

The effects of trabectedin on cardiovascular and respiratory function have been investigated *in vivo* (anesthetised Cynomolgus monkeys). A 1 hour infusion schedule was selected to attain maximum plasma levels ($C_{\text{max}}$ values) in the range of those observed in the clinic. The plasma trabectedin levels attained were $10.6 \pm 5.4$ ($C_{\text{max}}$), higher than those reached in patients after infusion of 1.8 ± 1.1 ng/ml and similar to those reached after administration of the same dose by 3 hour infusion ($C_{\text{max}}$ of 10.8 ± 3.7 ng/ml).

Myelosuppression and hepatotoxicity were identified as the primary toxicity for trabectedin. Findings observed included haematopoietic toxicity (severe leukopenia, anaemia, and lymphoid and bone marrow depletion) as well as increases in liver function tests, hepatocellular degeneration, intestinal epithelial necrosis, and severe local reactions at the injection site. Renal toxicological findings were detected in multi-cycle toxicity studies conducted in monkeys. These findings were secondary to severe local reaction at the administration site, and therefore uncertainly attributable to trabectedin; however, caution must be guaranteed in the interpretation of these renal findings, and treatment-related toxicity cannot be excluded.

Trabectedin is genotoxic both *in vitro* and *in vivo*. Long-term carcinogenicity studies have not been performed.

Fertility studies with trabectedin were not performed but limited histopathological changes were observed in the gonads in the repeat dose toxicity studies. Considering the nature of the compound (cytotoxic and mutagenic), it is likely to affect the reproductive capacity.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sucrose.

Potassium dihydrogen phosphate.

Phosphoric acid (for pH-adjustment).

Potassium hydroxide (for pH-adjustment).

6.2 Incompatibilities

Yondelis must not be mixed or diluted with other medicinal products except those mentioned in section 6.6.

6.3 Shelf life

Unopened vials: 24 months.

After reconstitution, chemical and physical stability has been demonstrated for 30 hours up to 25°C.

From a microbiological point of view, the reconstituted solution should be diluted and used immediately. If not diluted and used immediately, in-use storage times and conditions prior to use of the reconstituted product are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless reconstitution has taken place in controlled and validated aseptic conditions.
After dilution, chemical and physical stability has been demonstrated for 30 hours up to 25°C.

6.4 Special precautions for storage

Store in a refrigerator (2°C - 8°C).

For storage conditions of the reconstituted and diluted medicinal product, see section 6.3.

6.5 Nature and contents of container

Yondelis is supplied in a Type I colourless glass vial with a bromobutyl rubber stopper covered with an aluminium flip-off seal.

Each vial contains 0.25 mg of trabectedin.

Each outer carton contains one vial.

6.6 Special precautions for disposal and other handling

Preparation for intravenous infusion

Appropriate aseptic techniques must be used. Yondelis must be reconstituted and further diluted prior to infusion. Each vial containing 0.25 mg of trabectedin is reconstituted with 5 ml of sterile water for injections. The solution obtained has a concentration of 0.05 mg/ml and is for single-use only.

Instructions for reconstitution

A syringe is used to inject 5 ml of sterile water for injections into the vial. Shake the vial until complete dissolution. The reconstituted solution results in a clear, colourless or slightly yellowish solution, essentially free of visible particles.

This reconstituted solution contains 0.05 mg/ml of trabectedin. It requires further dilution and is for single-use only

Instructions for dilution

The reconstituted solution should be diluted with sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose 50 mg/ml (5%) solution for infusion. The required volume should be calculated as follows:

\[
\text{Volume (ml)} = \frac{\text{BSA (m}^2\text{)} \times \text{individual dose (mg/m}^2\text{)}}{0.05 \text{ mg/ml}}
\]

BSA = Body Surface Area

The appropriate amount of solution should be withdrawn from the vial and added to an infusion bag containing \( \geq 500 \text{ ml of diluent (sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose 50 mg/ml (5%) solution for infusion)} \) if administration is to be made through a central venous line.

If central venous access is not feasible and a peripheral venous line has to be used, the reconstituted solution should be added to an infusion bag containing \( \geq 1,000 \text{ ml of diluent (sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose 50 mg/ml (5%) solution for infusion)} \).

Parenteral solutions should be inspected visually for particles prior to administration. Once the infusion is prepared, it should be administered immediately.
Instructions for handling and disposal

Yondelis is a cytotoxic anticancer medicinal product and, as with other potentially toxic compounds, caution should be exercised during handling. Procedures for proper handling and disposal of cytotoxic medicinal products must be followed. Personnel should be trained in the correct techniques to reconstitute and dilute the medicinal product and should wear protective clothing including mask, goggles and gloves during the reconstitution and dilution. Pregnant staff must be excluded from working with this medicinal product.

Accidental contact with the skin, eyes or mucous membranes must be treated immediately with copious amounts of water.

Any unused product or waste material should be disposed of in accordance with local requirements for cytotoxic medicinal products.

No incompatibilities have been observed between Yondelis and polyvinylchloride (PVC) and polyethylene (PE) bags and tubing, and titanium implantable vascular access systems.

7. MARKETING AUTHORISATION HOLDER

Pharma Mar, S.A.
Avda. de los Reyes 1, Polígono Industrial La Mina
28770 Colmenar Viejo (Madrid)
Spain

8. MARKETING AUTHORISATION NUMBER(S)

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

10. DATE OF REVISION OF THE TEXT
1. **NAME OF THE MEDICINAL PRODUCT**

Yondelis 1 mg powder for concentrate for solution for infusion.

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each vial contains 1 mg of trabectedin.

1 ml of reconstituted solution contains 0.05 mg of trabectedin.

**Excipients:**

Each vial contains 8 mg of potassium and 0.4 g of sucrose.

For a full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Powder for concentrate for solution for infusion.

White to off-white powder.

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**

Yondelis is indicated for the treatment of patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.

4.2 **Posology and method of administration**

Yondelis must be administered under the supervision of a physician experienced in the use of chemotherapy. Its use should be confined to qualified oncologists or other health professionals specialised in the administration of cytotoxic agents.

The recommended dose is 1.5 mg/m² body surface area, administered as an intravenous infusion over 24 hours with a three-week interval between cycles. Administration through a central venous line is strongly recommended (see section 6.6).

All patients must receive 20 mg of dexamethasone intravenously 30 minutes prior to Yondelis; not only as anti-emetic prophylaxis, but also because it appears to provide hepatoprotective effects. Additional anti-emetics may be administered as needed.

The following criteria are required to allow treatment with Yondelis:

- Absolute neutrophil count (ANC) ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Bilirubin ≤ upper limit of normal (ULN)
- Alkaline phosphatase ≤ 2.5 ULN (consider hepatic isoenzymes 5-nucleotidase or GGT, if the elevation could be osseous in origin).
- Albumin ≥ 25 g/l.
- Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤ 2.5 x ULN
- Creatinine clearance $\geq 30$ ml/min
- Creatine phosphokinase (CPK) $\leq 2.5$ ULN
- Haemoglobin $\geq 9$ g/dl

The same criteria as above must be met prior to re-treatment. Otherwise treatment must be delayed for up to 3 weeks until the criteria are met.

Additional monitoring of haematological parameters bilirubin, alkaline phosphatase, aminotransferases and CPK should occur weekly during the first two cycles of therapy, and at least once between treatments in subsequent cycles.

The same dose should be given for all cycles provided that no grade 3-4 toxicities are seen and that the patient fulfils the re-treatment criteria.

**Dose adjustments during treatment**

Prior to re-treatment, patients must fulfil the baseline criteria defined above. If any of the following events occur at any time between cycles, the dose must be reduced to 1.2 mg/m² for subsequent cycles:

- Neutropenia $< 500$/mm³ lasting for more than 5 days or associated with fever or infection
- Thrombocytopenia $< 25,000$/mm³
- Increase of bilirubin $> \text{ULN}$ and/or alkaline phosphatase $> 2.5 \times \text{ULN}$
- Increase of aminotransferases (AST or ALT) $> 2.5 \times \text{ULN}$ which has not recovered by day 21
- Any other grade 3 or 4 adverse reactions (such as nausea, vomiting, fatigue)

Once a dose has been reduced because of toxicity, dose escalation in the subsequent cycles is not recommended. If any of these toxicities reappear in subsequent cycles in a patient exhibiting clinical benefit, the dose may be further reduced to 1 mg/m². In the event that further dose reductions are necessary, treatment discontinuation should be considered.

**Duration of treatment**

In clinical trials, there were no pre-defined limits to the number of cycles administered. Treatment continued whilst clinical benefit was noted. Trabectedin has been administered for 6 or more cycles in 168 out of 569 (29.5%) patients treated with the proposed dose and schedule. This regime has been used for up to 38 cycles. No cumulative toxicities have been observed in patients treated with multiple cycles.

**Special patient populations**

*Paediatric patients*

The safety and efficacy of trabectedin in paediatric patients have not yet been established. Therefore, this medicinal product must not be used in children and adolescents until further data become available.

*Elderly patients*

No specific studies in elderly patients have been performed. Overall 20% of the 1164 patients in the integrated safety analysis were over 65 years. No relevant differences in the safety profile were seen in this patient population. It seems that plasma clearance and distribution volume of trabectedin are not influenced by age. Therefore, dose adjustments based uniquely on age criteria are not routinely recommended.
Patients with impaired hepatic function

No studies with the proposed regime have been conducted in patients with liver dysfunction. Thus, data are not available to recommend a lower starting dose in patients with hepatic impairment. However, special caution is advised and dose adjustments may be necessary in these patients since systemic exposure is probably increased and the risk of hepatotoxicity might be increased. Patients with elevated bilirubin must not be treated with Yondelis (see section 4.4).

Patients with impaired renal function

Studies including patients with severe renal insufficiency (creatinine clearance < 30 ml/min) have not been conducted and therefore Yondelis must not be used in this patient population (see section 4.4). Considering the pharmacokinetic characteristics of trabectedin (see section 5.2), no dose adjustments are warranted in patients with mild or moderate renal impairment.

For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.

4.3 Contraindications

- Hypersensitivity to trabectedin or to any of the excipients
- Concurrent serious or uncontrolled infection
- Breast-feeding (see section 4.6)
- Combination with yellow fever vaccine (see section 4.4)

4.4 Special warnings and precautions for use

Hepatic impairment

Patients must meet specific criteria on hepatic function parameters to start treatment with Yondelis. Since systemic exposure to trabectedin is probably increased due to hepatic impairment and therefore the risk of hepatotoxicity might be increased, patients with clinically relevant liver diseases, such as active chronic hepatitis, must be closely monitored and the dose adjusted if needed. Patients with elevated bilirubin must not be treated with trabectedin (see section 4.2).

Renal impairment

Creatinine clearance must be monitored prior to and during treatment. Trabectedin must not be used in patients with creatinine clearance < 30 ml/min (see section 4.2).

Neutropenia and thrombocytopenia

Grades 3 or 4 neutropenia and thrombocytopenia associated with trabectedin therapy have been very commonly reported. A full blood cell count including differential and platelet count must be performed at baseline, weekly for the first two cycles and then once between cycles (see section 4.2). Patients who develop fever should promptly seek medical attention. If this occurs, active supportive therapy should be started immediately.

Nausea and vomiting

Anti-emetic prophylaxis with dexamethasone must be administered to all patients (see section 4.2).

Rhabdomyolysis and severe CPK elevations (> 10 x ULN)

Trabectedin must not be used in patients with CPK > 2.5 ULN (see section 4.2). Rhabdomyolysis has been uncommonly reported, usually in association with myelotoxicity, severe liver function test abnormalities and/or renal failure. Therefore, CPK should be closely monitored whenever a patient
may be experiencing any of these toxicities. If rhabdomyolysis occurs, supportive measures such as parenteral hydration, urine alkalinisation and dialysis should be promptly established, as indicated. Treatment with Yondelis should be discontinued until the patient fully recovers.

Caution should be taken if medicinal products associated with rhabdomyolysis (e.g. statins), are administered concomitantly with trabectedin, since the risk of rhabdomyolysis may be increased

**Liver Function Test (LFT) abnormalities**

Reversible acute increases in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) have been reported in most patients. Yondelis must not be used in patients with elevated bilirubin. Patients with increases in AST, ALT and alkaline phosphatase between cycles may necessitate dose reduction (see section 4.2).

**Injection site reactions**

The use of central venous access is strongly recommended (see section 4.2). Patients may develop a potentially severe injection site reaction when trabectedin is administered through a peripheral venous line.

**Others**

Co-administration of Yondelis with potent inhibitors of the enzyme CYP3A4 should be avoided (see section 4.5). If this is not possible, close monitoring of toxicities are required and dose reductions of trabectedin should be considered.

Caution should be taken if medicinal products associated with hepatotoxicity are administered concomitantly with trabectedin, since the risk of hepatotoxicity may be increased.

Concomitant use of trabectedin with phenytoin may reduce phenytoin absorption leading to an exacerbation of convulsions. Combination of trabectedin with phenytoin or live attenuated vaccines is not recommended and with yellow fever vaccine is specifically contraindicated (see sections 4.3 and 4.5).

The concomitant use of trabectedin with alcohol must be avoided (see section 4.5).

Men in fertile age and women of childbearing potential must use effective contraception during treatment and 3 months thereafter for women and immediately inform the treating physician if a pregnancy occurs, and 5 months after treatment for men (see section 4.6).

This medicine contains potassium, less than 1 mmol (39 mg) per vial, i.e. essentially “potassium-free”.

### 4.5 Interaction with other medicinal products and other forms of interaction

**Effects of other substances on trabectedin**

*In vivo* interaction studies have not been performed. Since trabectedin is metabolised mainly by CYP3A4, co-administration of substances that inhibit this isoenzyme e.g. ketoconazole, fluconazole ritonavir or clarithromycin could decrease metabolism and increase trabectedin concentrations. If such combinations are needed, close monitoring of toxicities is required (see section 4.4). Likewise co-administration with potent inducers of this enzyme (e.g. rifampicin, phenobarbital, Saint John’s Wort) may decrease the systemic exposure to trabectedin.

Alcohol consumption must be avoided during treatment with trabectedin due to the hepatotoxicity of the medicinal product (see section 4.4).
Preclinical data have demonstrated that trabectedin is a substrate to P-gp. Concomitant administration of inhibitors of Pgp, e.g. cyclosporine and verapamil, may alter trabectedin distribution and/or elimination. The relevance of this interaction e.g. CNS toxicity has not been established. Caution should be taken in such situations.

4.6 Pregnancy and lactation

Pregnancy

No sufficient clinical data on exposed pregnancies are available. However, based on its known mechanism of action, trabectedin may cause serious birth defects when administered during pregnancy. Trabectedin should not be used during pregnancy unless clearly necessary. If it is used during pregnancy, the patient must be informed of the potential risk to the foetus (see section 5.3) and be monitored carefully. If trabectedin is used at the end of pregnancy, potential adverse reactions should be monitored carefully in the newborns.

Fertility

Men in fertile age and women of childbearing potential must use effective contraception during treatment and 3 months thereafter for women and immediately inform the treating physician if a pregnancy occurs (see section 5.3) and 5 months after treatment for men (see section 4.4).

Trabectedin can have genotoxic effects. Advice on conservation of sperm should be sought prior to treatment because of the possibility of irreversible infertility due to therapy with Yondelis. If pregnancy occurs during treatment the possibility of genetic counselling should be considered. Genetic counselling is also recommended for patients wishing to have children after therapy.

Lactation

It is not known whether trabectedin is excreted in human milk. The excretion of trabectedin in milk has not been studied in animals. Breast-feeding is contraindicated during treatment and 3 months thereafter (see section 4.3).

4.7 Effects on ability to drive and use machines

No studies on the effects of the ability to drive and to use machines have been performed. However, fatigue and/or asthenia have been reported in patients receiving trabectedin. Patients who experience any of these events during therapy must not drive or operate machines.

4.8 Undesirable effects

Unless otherwise specified, the following safety profile of Yondelis is based on the evaluation in clinical trials of 569 patients treated up to April 2007 with the recommended treatment regime in several cancer types including soft tissue sarcoma, breast cancer, osteosarcoma, ovarian cancer, GIST, melanoma and renal carcinoma.

Approximately 91% of patients can be expected to have adverse reactions of any grade. Around 40% of patients are expected to have adverse reactions of grade 3 or 4 severity. The most common adverse reactions of any severity grade were nausea, fatigue, vomiting, anorexia, neutropenia, and increases in AST/ALT.
Fatal adverse reactions have occurred in 1.9% of patients. They were often the result of a combination of events including pancytopenia, febrile neutropenia, some of them with sepsis, hepatic involvement, renal failure and rhabdomyolysis.

Adverse reactions

The frequencies of the adverse reactions reported below are classified as very common (≥ 1/10), common (≥ 1/100 to < 1/10) and uncommon (≥ 1/1000 to < 1/100).

The table below displays the adverse reactions reported in ≥ 1% of patients according to the standard MedDRA system organ class. Both adverse events and laboratory values have been used to provide frequencies. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Adverse reactions reported in ≥ 1% of patients in clinical trials at the recommended regime [1.5 mg/m², 24 hour infusion every 3 weeks (24-h q3wk)]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investigations</td>
<td>Very Common Blood creatine phosphokinase increased, Blood creatinine increased, Blood albumin decreased Common Weight decreased</td>
</tr>
<tr>
<td>Blood and Lymphatic System Disorders</td>
<td>Very Common Neutropenia, Thrombocytopenia, Anaemia, Leukopenia Common Febrile neutropenia</td>
</tr>
<tr>
<td>Nervous System Disorders</td>
<td>Very Common Headache Common Peripheral sensory neuropathy, Dysgeusia, Dizziness, Paraesthesia</td>
</tr>
<tr>
<td>Respiratory, Thoracic and Mediastinal Disorders</td>
<td>Common Dyspnoea, Cough</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Very Common Vomiting, Nausea, Constipation Common Diarrhoea, Stomatitis, Abdominal pain, Dyspepsia, Upper abdominal pain</td>
</tr>
<tr>
<td>Skin and Subcutaneous Tissue Disorders</td>
<td>Common Alopecia</td>
</tr>
<tr>
<td>Musculoskeletal and Connective Tissue Disorders</td>
<td>Common Myalgia, Arthralgia, Back pain</td>
</tr>
<tr>
<td>Metabolism and Nutrition Disorders</td>
<td>Very Common Anorexia Common Dehydration, Decreased appetite, Hypokalaemia</td>
</tr>
<tr>
<td>Infections and Infestations</td>
<td>Common Infection</td>
</tr>
<tr>
<td>Vascular Disorders</td>
<td>Common Hypotension, Flushing</td>
</tr>
<tr>
<td>General Disorders and Administration Site Conditions</td>
<td>Very Common Fatigue, Asthenia Common Pyrexia, Oedema, Oedema peripheral, Injection site reaction</td>
</tr>
</tbody>
</table>
System Organ Class | Adverse reactions reported in ≥ 1% of patients in clinical trials at the recommended regime [1.5 mg/m², 24 hour infusion every 3 weeks (24-h q3wk)]
---|---
Hepatobiliary Disorders | Very Common
Hyperbilirubinemia, Alanine aminotransferase increased, Aspartate aminotransferase increased, Blood alkaline phosphatase increased, Gamma-glutamyltransferase increased
Psychiatric Disorders | Common
Insomnia

Most frequent adverse reactions

**Blood and Lymphatic system disorders**

*Neutropenia:* Neutropenia occurred in 77% of patients. Grade 3 and 4 neutropenia occurred in 26% and 24% of patients respectively. The analysis per cycle showed that neutropenia of grade 3 and 4 occurred in approximately 19% and 8% of cycles respectively Febrile neutropenia occurred in 2% of patients and in < 1% of cycles.

Neutropenia followed a predictable pattern of rapid onset and reversibility, and was rarely associated with fever or infection.

*Thrombocytopenia:* Grade 3 and 4 thrombocytopenia occurred in 11% and 2% of patients respectively. The analysis per cycle showed that thrombocytopenia of grade 3 and 4 occurred in approximately 3% and < 1% of cycles respectively. Bleeding events associated to thrombocytopenia occurred in < 1% of patients.

*Anaemia:* Anaemia occurred in 93% of patients although 46% of patients were anaemic at baseline. Grade 3 and 4 anaemia occurred in 10% and 3% of patients respectively. The analysis per cycle showed that anaemia of grade 3 and 4 occurred in approximately 3% and 1% of cycles respectively.

**Hepatobiliary disorders**

*AST/ALT increases:* Transient grade 3 increases of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were observed in 38% and 44% of the patients and grade 4 elevations in 3% and 7% of the patients, respectively. The median time to reach the peak values was 5 days for both AST and ALT. Most of the values had decreased to grade 1 or resolved by day 14-15 (see section 4.4). Grade 3 elevations of AST and ALT occurred in 12% and 20% of cycles respectively. Grade 4 elevations of AST and ALT occurred in 1% and 2% of cycles respectively. Most transaminase elevations improved to grade 1 or to pre-retreatment levels within 15 days, and less than 2% of cycles had recovering times longer than 25 days. ALT and AST increases did not follow a cumulative pattern but showed a tendency towards less severe elevations over time.

*Hyperbilirubinemia:* Grades 1 to 2 bilirubin increases were observed in 23% of the patients. Grade 3 hyperbilirubinemia occurred in 1% of patients. Bilirubin peaks approximately a week after onset and resolves approximately two weeks after onset.

Clinical manifestations of severe hepatic injury were uncommon with a lower than 1% incidence of individual signs and symptoms including jaundice, hepatomegaly or liver pain. Mortality in the presence of hepatic injury occurred in less than 1% of patients.

Other adverse reactions

*Nausea, vomiting, diarrhoea and constipation:* Nausea and vomiting were reported in 63 and 38.5% of patients respectively. Grade 3-4 nausea and vomiting were reported in 6% and 6.5% of patients, respectively. Grade 3-4 diarrhoea and constipation were reported in less than 1% of patients.
Stomatitis: Grade 3-4 mucositis was reported in less than 1% of the patients.

Fatigue/Asthenia: Grade 3-4 fatigue/asthenia occurred in 9 and 1% of patients respectively.

Anorexia: Grade 3-4 anorexia occurred in less than 1% of the patients.

CPK elevations and rhabdomyolysis: CPK elevations of any grade were observed in 26% of patients. Grade 3 or 4 increases of CPK were observed in 4% of patients. CPK increases in association with rhabdomyolysis were reported in less than 1% of patients.

Dyspnoea: Grade 3-4 dyspnoea reported as trabectedin related occurred in 2% of the patients.

Alopecia: Alopecia was reported in approximately 3% of all patients, of which the majority was grade 1 alopecia.

4.9 Overdose

There is limited data on the effects of trabectedin overdose. The major anticipated toxicities are gastrointestinal, bone marrow suppression and hepatic toxicity. There is no specific antidote for trabectedin currently available. In the event of an overdose, patients should be closely monitored and symptomatic supportive care measures instituted as required.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agent, ATC code: L01CX01.

Mechanism of action

Trabectedin binds to the minor groove of DNA, bending the helix to the major groove. This binding to DNA triggers a cascade of events affecting several transcription factors, DNA binding proteins, and DNA repair pathways, resulting in perturbation of the cell cycle. Trabectedin has been shown to exert antiproliferative in vitro and in vivo activity against a range of human tumour cell lines and experimental tumours, including malignancies such as sarcoma, breast, non-small cell lung, ovarian and melanoma.

Clinical efficacy

The efficacy and safety of trabectedin is based in a randomised trial in patients with locally advanced or metastatic liposarcoma or leiomyosarcoma, whose disease had progressed or relapsed after treatment with at least anthracyclines and ifosfamide. In this trial trabectedin was administered either at 1.5 mg/m² as a 24-hour intravenous infusion every 3 weeks or at 0.58 mg/m² weekly as a 3-hour intravenous infusion for 3-weeks of a 4-week cycle. The protocol specified final time to progression (TTP) analysis showed a 26.6% reduction in the relative risk of progression for patients treated in the 24-h q3wk group (Hazard Ratio = 0.734 CI 0.554-0.974). Median TTP values were 3.7 months (CI: 2.1-5.4 m) in the 24-h q3wk group and 2.3 months (CI: 2.0-3.5 m) in the 3-h qwk group (p=0.0302). No significant differences were detected in overall survival (OS). Median OS with the 24-h q3wk regime was 13.9 months (CI: 12.5-18.6) and 60.2% of patients were alive at 1 year (CI: 52.0-68.5%).

Additional efficacy data are available from 3 single-arm Phase II trials with similar populations treated with the same regime. These trials evaluated a total of 100 patients with lipo and leiomyosarcoma and 83 patients with other types of sarcoma.
This medicinal product has been authorised under “Exceptional Circumstances”. This means that due to the rarity of the disease it has not been possible to obtain complete information on this medicinal product.

The European Medicines Agency (EMEA) will review any new information which may become available every year and this SPC will be updated as necessary.

5.2 Pharmacokinetic properties

Systemic exposure after administration as a 24 hour constant rate intravenous infusion is dose proportional at doses up to and including 1.8 mg/m². Trabectedin pharmacokinetic profile is consistent with a multiple-compartment disposition model.

Following intravenous administration, trabectedin demonstrates a high apparent volume of distribution, consistent with extensive tissue and plasma protein binding (94 to 98% of trabectedin in plasma is protein bound). The distribution volume at steady state of trabectedin in human subjects exceeds 5000 l.

Cytochrome P450 3A4 is the major cytochrome P450 isozyme responsible for the oxidative metabolism of trabectedin at clinically relevant concentrations. Other P450 enzymes may contribute to metabolism. Trabected in does not induce or inhibit major cytochrome P450 enzymes.

Renal elimination of unchanged trabectedin in humans is low (less than 1%). The terminal half-life is long (population value of the terminal elimination phase: 180-hr). After a dose of radiolabelled trabectedin administered to cancer patients, faecal mean (SD) recovery of total radioactivity is 58% (17%), and urinary mean (SD) recovery is 5.8% (1.73%). Based on the population estimate for plasma clearance of trabectedin (31.5 l/h) and blood/plasma ratio (0.89), the clearance of trabectedin in whole blood is approximately 35 l/h. This value is approximately one-half the rate of human hepatic blood flow. Thus the trabectedin extraction ratio can be considered moderate. The inter-patient variability of the population estimate for plasma clearance of trabectedin was 51% and intra-patient variability was 28%.

Special populations

A population pharmacokinetic analysis indicated that the plasma clearance of trabectedin is not influenced by age (range 19-83 years), or gender. The effects of race and ethnicity on trabectedin pharmacokinetics have not been studied.

Impaired renal function

There is no relevant influence of renal function measured by creatinine clearance on trabectedin pharmacokinetics within the range of values (≥ 34.4 ml/min) present in the patients included in the clinical studies. No data are available in patients with a creatinine clearance of less than 34.4 ml/min. The low recovery (< 9% in all studied patients) of total radioactivity in the urine after a single dose of 14C-labelled trabectedin indicates that renal impairment has little influence on the elimination of trabectedin or its metabolites.

Impaired hepatic function

Although the population analysis showed no relationship between the serum liver enzymes concentrations and the plasma clearance of trabectedin, systemic exposure to trabectedin may be increased in patients with hepatic impairment; therefore close monitoring of toxicity is warranted.
5.3 Preclinical safety data

Preclinical data indicate that trabectedin has limited effect on the cardiovascular, respiratory and central nervous system at exposures below the therapeutic clinical range, in terms of AUC.

The effects of trabectedin on cardiovascular and respiratory function have been investigated \textit{in vivo} (anesthetised Cynomolgus monkeys). A 1 hour infusion schedule was selected to attain maximum plasma levels ($C_{\text{max}}$ values) in the range of those observed in the clinic. The plasma trabectedin levels attained were $10.6 \pm 5.4$ ($C_{\text{max}}$), higher than those reached in patients after infusion of $1500 \, \mu\text{g/m}^2$ for 24 ($C_{\text{max}}$ of $1.8 \pm 1.1 \, \text{ng/ml}$) and similar to those reached after administration of the same dose by 3 hour infusion ($C_{\text{max}}$ of $10.8 \pm 3.7 \, \text{ng/ml}$).

Myelosupression and hepatotoxicity were identified as the primary toxicity for trabectedin. Findings observed included haematopoietic toxicity (severe leukopenia, anaemia, and lymphoid and bone marrow depletion) as well as increases in liver function tests, hepatocellular degeneration, intestinal epithelial necrosis, and severe local reactions at the injection site. Renal toxicological findings were detected in multi-cycle toxicity studies conducted in monkeys. These findings were secondary to severe local reaction at the administration site, and therefore uncertainly attributable to trabectedin; however, caution must be guaranteed in the interpretation of these renal findings, and treatment-related toxicity cannot be excluded.

Trabectedin is genotoxic both \textit{in vitro} and \textit{in vivo}. Long-term carcinogenicity studies have not been performed.

Fertility studies with trabectedin were not performed but limited histopathological changes were observed in the gonads in the repeat dose toxicity studies. Considering the nature of the compound (cytotoxic and mutagenic), it is likely to affect the reproductive capacity.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sucrose.

Potassium dihydrogen phosphate.

Phosphoric acid (for pH-adjustment).

Potassium hydroxide (for pH-adjustment).

6.2 Incompatibilities

Yondelis must not be mixed or diluted with other medicinal products except those mentioned in section 6.6.

6.3 Shelf life

Unopened vials: 24 months.

After reconstitution, chemical and physical stability has been demonstrated for 30 hours up to 25°C.

From a microbiological point of view, the reconstituted solution should be diluted and used immediately. If not diluted and used immediately, in-use storage times and conditions prior to use of the reconstituted product are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless reconstitution has taken place in controlled and validated aseptic conditions.
After dilution, chemical and physical stability has been demonstrated for 30 hours up to 25ºC.

6.4 Special precautions for storage

Store in a refrigerator (2ºC - 8ºC).

For storage conditions of the reconstituted and diluted medicinal product, see section 6.3.

6.5 Nature and contents of container

Yondelis is supplied in a Type I colourless glass vial with a bromobutyl rubber stopper covered with an aluminium flip-off seal.

Each vial contains 1 mg of trabectedin.

Each outer carton contains one vial.

6.6 Special precautions for disposal and other handling

Preparation for intravenous infusion

Appropriate aseptic techniques must be used. Yondelis must be reconstituted and further diluted prior to infusion. Each vial containing 1 mg of trabectedin is reconstituted with 20 ml of sterile water for injections. The solution obtained has a concentration of 0.05 mg/ml and is for single-use only.

Instructions for reconstitution

A syringe is used to inject 20 ml of sterile water for injections into the vial. Shake the vial until complete dissolution. The reconstituted solution results in a clear, colourless or slightly yellowish solution, essentially free of visible particles.

This reconstituted solution contains 0.05 mg/ml of trabectedin. It requires further dilution and is for single-use only.

Instructions for dilution

The reconstituted solution should be diluted with sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose 50 mg/ml (5%) solution for infusion. The required volume should be calculated as follows:

\[
\text{Volume (ml)} = \frac{\text{BSA (m}^2\text{)} \times \text{individual dose (mg/m}^2\text{)}}{0.05 \text{ mg/ml}}
\]

BSA = Body Surface Area

The appropriate amount of solution should be withdrawn from the vial and added to an infusion bag containing ≥ 500 ml of diluent (sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose 50 mg/ml (5%) solution for infusion) if administration is to be made through a central venous line.

If central venous access is not feasible and a peripheral venous line has to be used, the reconstituted solution should be added to an infusion bag containing ≥ 1,000 ml of diluent (sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose 50 mg/ml (5%) solution for infusion).

Parenteral solutions should be inspected visually for particles prior to administration. Once the infusion is prepared, it should be administered immediately.
Instructions for handling and disposal

Yondelis is a cytotoxic anticancer medicinal product and, as with other potentially toxic compounds, caution should be exercised during handling. Procedures for proper handling and disposal of cytotoxic medicinal products must be followed. Personnel should be trained in the correct techniques to reconstitute and dilute the medicinal product and should wear protective clothing including mask, goggles and gloves during the reconstitution and dilution. Pregnant staff must be excluded from working with this medicinal product.

Accidental contact with the skin, eyes or mucous membranes must be treated immediately with copious amounts of water.

Any unused product or waste material should be disposed of in accordance with local requirements for cytotoxic medicinal products.

No incompatibilities have been observed between Yondelis and polyvinylchloride (PVC) and polyethylene (PE) bags and tubing, and titanium implantable vascular access systems.

7. MARKETING AUTHORIZERATION HOLDER

Pharma Mar, S.A.
Avda. de los Reyes 1, Polígono Industrial La Mina
28770 Colmenar Viejo (Madrid)
Spain

8. MARKETING AUTHORIZATION NUMBER(S)

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORIZATION

10. DATE OF REVISION OF THE TEXT
ANNEX II

A. MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OF THE MARKETING AUTHORISATION

C. SPECIFIC OBLIGATIONS TO BE FULFILLED BY THE MARKETING AUTHORISATION HOLDER
A. MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

Pharma Mar S.A.
Polígono Industrial La Mina
Avda. de los Reyes, 1
E-28770 Colmenar Viejo
Madrid
Spain

B. CONDITIONS OF THE MARKETING AUTHORISATION

• CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER

Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).

• CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

Not applicable.

• OTHER CONDITIONS

Pharmacovigilance system
The MAH must ensure that the system of pharmacovigilance, as described in version 1.0 presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market.

Risk Management Plan
The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in version 3.0 of the Risk Management Plan (RMP) presented in Module 1.8.2. of the Marketing Authorisation Application and any subsequent updates of the RMP agreed by the CHMP.

As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).

In addition, an updated RMP should be submitted

• When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities
• Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached
• At the request of the EMEA
C. SPECIFIC OBLIGATIONS TO BE FULFILLED BY THE MARKETING AUTHORISATION HOLDER

The Marketing Authorisation Holder shall complete the following programme of studies within the specified time frame, the results of which shall form the basis of the annual reassessment of the benefit/risk profile.

Clinical aspects:

To conduct further investigations in order to elucidate whether predictors of response to Yondelis in patients with soft tissue sarcoma can be identified. This should include a proposal to assess the efficacy and safety of Yondelis in a sub-group of patients with myxoid liposarcoma and will be submitted to the EMEA by 4Q 2007.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

*Outer carton – 0.25 mg vial*

---

### 1. NAME OF THE MEDICINAL PRODUCT

Yondelis 0.25 mg powder for concentrate for solution for infusion
Trabectedin

---

### 2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each vial contains 0.25 mg of trabectedin.
1 ml of reconstituted solution contains 0.05 mg of trabectedin.

---

### 3. LIST OF EXCIPIENTS

Also contains: sucrose, potassium dihydrogen phosphate, phosphoric acid and potassium hydroxide.
See package leaflet for further information.

---

### 4. PHARMACEUTICAL FORM AND CONTENTS

Powder for concentrate for solution for infusion
1 vial of 0.25 mg trabectedin

---

### 5. METHOD AND ROUTE(S) OF ADMINISTRATION

For intravenous use after reconstitution and further dilution.
Read the package leaflet before use.

---

### 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

---

### 7. OTHER SPECIAL WARNING(S), IF NECESSARY

---

### 8. EXPIRY DATE

EXP: {MM/YYYY}
9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. For storage conditions for the reconstituted and diluted solutions, see the package leaflet.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

Cytotoxic product. Discard any unused product or waste material in accordance with local requirements.

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Pharma Mar, S.A.
Avda. de los Reyes 1
Pol. Ind. La Mina
28770 Colmenar Viejo (Madrid)
Spain

12. MARKETING AUTHORISATION NUMBER(S)

EU/0/00/000/000

13. BATCH NUMBER

Lot: {number}

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Justification for not including Braille accepted.
**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**Vial label** – 0.25 mg vial

1. **NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION**

   Yondelis 0.25 mg powder for concentrate for solution for infusion  
   Trabectedin  
   IV use

2. **METHOD OF ADMINISTRATION**

3. **EXPIRY DATE**

   EXP: {MM/YYYY}

4. **BATCH NUMBER**

   Lot: {number}

5. **CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT**

   0.25 mg trabectedin

6. **OTHER**
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

Outer carton – 1 mg vial

1. NAME OF THE MEDICINAL PRODUCT

Yondelis 1 mg powder for concentrate for solution for infusion
Trabectedin

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each vial contains 1 mg of trabectedin.
1 ml of reconstituted solution contains 0.05 mg of trabectedin.

3. LIST OF EXCIPIENTS

Also contains: sucrose, potassium dihydrogen phosphate, phosphoric acid and potassium hydroxide.
See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Powder for concentrate for solution for infusion
1 vial of 1 mg trabectedin

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For intravenous use after reconstitution and further dilution.
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP: {MM/YYYY}
9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator. For storage conditions for the reconstituted and diluted solutions, see the package leaflet.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

Cytotoxic product. Discard any unused product or waste material in accordance with local requirements.

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Pharma Mar, S.A.
Avda. de los Reyes 1
Pol. Ind. La Mina
28770 Colmenar Viejo (Madrid)
Spain

12. MARKETING AUTHORISATION NUMBER(S)

EU/0/00/000/000

13. BATCH NUMBER

Lot: {number}

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Justification for not including Braille accepted.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Vial label – 1 mg vial

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Yondelis 1 mg powder for concentrate for solution for infusion
Trabectedin
IV use

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

EXP: {MM/YYYY}

4. BATCH NUMBER

Lot: {number}

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

1 mg trabectedin

6. OTHER
B. PACKAGE LEAFLET
Package Leaflet: Information for the User

Yondelis 0.25 mg powder for concentrate for solution for infusion
Yondelis 1 mg powder for concentrate for solution for infusion
Trabectedin

Read all of this leaflet carefully before you start using this medicine.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.

In this leaflet:
1. What Yondelis is and what it is used for
2. Before you are given Yondelis
3. How to use Yondelis
4. Possible side effects
5. How to store Yondelis
6. Further information

1. WHAT YONDELIS IS AND WHAT IT IS USED FOR

Yondelis is an anti-cancer medicine that works by preventing the tumour cells from multiplying.

Yondelis is used for the treatment of patients with advanced soft tissue sarcoma, when previous medicines have been unsuccessful or the patients are unsuited to receive them. Soft tissue sarcoma is a malignant disease that starts somewhere in the soft tissues, such as the muscles, fat or other tissues (for example cartilages or vessels).

2. BEFORE YOU ARE GIVEN YONDELIS

Do not use Yondelis:
- if you are allergic (hypersensitive) to trabectedin or any of the other ingredients of Yondelis
- if you have any serious infections
- if you are breast-feeding
- if you will receive yellow fever vaccine.

Take special care with Yondelis:

Yondelis must not be used if you have severe liver or kidney damage. Tell your doctor if you know or suspect that you have any liver or kidney problems before starting the treatment with Yondelis.

You should seek medical attention immediately if any of the following conditions appear:

• If you develop a fever as Yondelis may cause side-effects affecting your blood and liver.
• If you still feel sick, vomit or are unable to drink fluids and therefore pass less urine despite being given anti-sickness medicines.

• If you experience severe muscle pain as it could be a sign of rhabdomyolysis (damage to the muscles, see section 4).

Yondelis must not be used in children and adolescents since safety and efficacy have not yet been studied in this age group.

Using other medicines

Please tell your doctor if you plan to take, are taking or have recently taken any other medicines, including medicines obtained without a prescription, vaccines and herbal medicines.

You must not use Yondelis if you will receive yellow fever vaccine and it is not recommended that you use Yondelis if you will receive a vaccine containing live virus particles. The effect of medicines containing phenytoin (for epilepsy) may be decreased if given together with Yondelis and this is therefore not recommended.

If you use other medicines, you may need to be closely monitored as the effects of Yondelis might be decreased (examples are medicines containing rifampicin (for bacterial infections), phenobarbital (for epilepsy) or St.John’s Wort (Hypericum perforatum, herbal medicine for depression)) or increased (examples are medicines containing ketoconazole or fluconazole (for fungal infections), ritonavir (for HIV infection), clarithromycin (for bacterial infections), ciclosporin (inhibit the defensive system of the body) or verapamil (for high blood pressure and heart conditions)) as a result.

If you are given a medicine that might cause damage to the liver or to the muscles (rhabdomyolysis), you may need to be closely monitored when using Yondelis together with this medicine, as there could be an increased risk of damage. Medicines containing statins (for lowering cholesterol levels and preventing cardiovascular disease) is an example of medicines that may cause muscle damage.

Using Yondelis with food and drink

Alcohol consumption must be avoided during treatment with Yondelis as this may harm the liver.

Pregnancy and breast-feeding

Pregnancy
You should not use Yondelis if you are pregnant or if you/your partner are trying to become pregnant as Yondelis may harm the unborn baby. If you are pregnant or you think you may be pregnant, you must tell your doctor immediately. The doctor may prescribe Yondelis during pregnancy in certain circumstances.

Adequate contraceptive precautions must be used by men in fertile age and women of childbearing potential when receiving Yondelis and for 3 months following the end of treatment for women and 5 months following the end of treatment for men. If a pregnancy should occur you must tell your doctor immediately and genetic counselling is recommended since Yondelis can cause genetic damage.

Genetic counselling is also recommended for patients wishing to have children after therapy. Male patients should seek advice on conservation of sperm prior to treatment because of the risk of irreversible infertility due to therapy with Yondelis.
Breast-feeding

Yondelis must not be given to patients who are breast-feeding. Therefore you must stop breast-feeding before you start your treatment and you must not begin breast-feeding again until your doctor has confirmed that it is safe to do so.

Driving and using machines

During your treatment with Yondelis you may feel tired and experience a loss of strength. Do not drive or use any tools or machines if you are experiencing any of these side effects.

Important information about some of the ingredients of Yondelis

This medicine contains potassium, less than 1 mmol (39 mg) per vial, and can therefore be considered as essentially “potassium-free”.

3. HOW TO USE YONDELIS

Yondelis is given to you under the supervision of a physician experienced in the use of chemotherapy. Its use should be confined to qualified oncologists or other health professionals specialised in the administration of cytotoxic medicines.

The usual dose is 1.5 mg/m² of body surface area. During the treatment period, your doctor will carefully monitor you and decide the most appropriate dosage of Yondelis to give to you.

Before it is given to you, Yondelis is reconstituted and diluted and then put into a drip bag for intravenous use. Every time you are given Yondelis, it will take about 24 hours for all of the solution to enter your blood.

In order to avoid irritation at the site of injection it is recommended that Yondelis is given to you through a central venous line.

You will be given medicine before and as needed during the treatment with Yondelis in order to protect your liver and to reduce the risk of side effects such as feeling sick (nausea) and vomiting.

The infusion is given to you every 3 weeks.

The length of your whole treatment period will depend on your progress and how well you feel. Your doctor will tell you how long your treatment may last. If you have any further questions on the use of this medicine, ask your doctor.

4. POSSIBLE SIDE EFFECTS

Like all medicines, Yondelis can cause side effects, although not everybody gets them.

If you are not sure what the side effects below are, you should ask your doctor to explain them to you in more detail.

Very common (occurring in at least 1 in 10 patients):

- You may:
  - feel tired
  - feel short of breath (dyspnoea)
  - bruise more easily
  - have nose bleeds
  - be more prone to infections. An infection could also give you a raised temperature.
If you develop any of these symptoms you should seek medical attention immediately.

- Your doctor may require blood tests in certain situations in order to avoid that you develop damage to the muscles (rhabdomyolysis). In very severe cases this could lead to kidney failure. If you experience severe muscle pain, you should seek medical attention immediately.
- You could have increased levels of the yellow pigment bilirubin in the blood which might cause jaundice (a yellowing of the skin, mucous membranes and eyes).
- You may experience headache and a loss of strength.
- You may also lose your appetite, feel sick (nausea) or vomit, and become constipated. If you still feel sick, vomit or are unable to drink fluids and therefore pass less urine, despite being given anti-sickness medication, you should immediately seek medical help.
- Your doctor will order regular blood tests to detect any abnormalities in the blood.

Common (occurring in at least 1 in 100 patients):

- You may have fever. If you have a raised temperature you should seek medical attention immediately.
- You could also feel pain in your back, muscles and joints. There could be damage to your nerves which may result in muscle pain, weakness and numbness. You could experience general swelling or swelling of the limbs and a sensation of creeping on the skin.
- You may experience diarrhoea, loss of water from the body, inflammation of the mouth (stomatitis), pain in the abdomen, weight loss, digestive discomfort and a change in your sense of taste.
- You could have coughing.
- You may lose hair (alopecia).
- You could also experience dizziness, sleeping problems, low blood pressure and flushing.
- You may have a reaction at the site of injection

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.

5. HOW TO STORE YONDELIS

Keep out of the reach and sight of children.

Do not use Yondelis after the expiry date which is stated on the carton and the vial label after EXP. The expiry date refers to the last day of that month.

Store in a refrigerator (2ºC - 8ºC).

Information on in-use stability of the reconstituted and diluted solutions is included in the section for medical and healthcare professionals.
6.  FURTHER INFORMATION

What Yondelis contains:

- The active substance is trabectedin.
  Yondelis 0.25 mg: Each vial contains 0.25 mg of trabectedin
  Yondelis 1 mg: Each vial contains 1 mg of trabectedin.

- The other ingredients are sucrose, potassium dihydrogen phosphate, phosphoric acid (for pH-adjustment) and potassium hydroxide (for pH-adjustment).

What Yondelis looks like and contents of the pack

Yondelis is a powder for concentrate for solution for infusion. The powder has a white to off-white colour and comes in a glass vial.

Each carton contains 1 vial of either 0.25 mg or 1 mg of trabectedin.

Marketing Authorisation Holder and Manufacturer:

Pharma Mar, S.A.
Avda. de los Reyes 1
Poligono Industrial La Mina
28770 Colmenar Viejo (Madrid)
Spain

Tel: +34 91 846 60 00
Fax: +34 91 846 60 01

For any information about this medicine, please contact the Marketing Authorisation Holder.

This leaflet was last approved in {MM/YYYY}

This medicine has been authorised under “Exceptional Circumstances”. This means that because of the rarity of this disease it has been impossible to get complete information on this medicine.

The European Medicines Agency (EMEA) will review any new information on the medicine every year and this leaflet will be updated as necessary.

The following information is intended for medical or healthcare professionals only:

Instructions for use – preparation, handling and disposal

Appropriate procedures for proper handling and disposal of cytotoxic medicines must be followed. Any unused medicine or waste material should be disposed of in accordance with local requirements for cytotoxic medicines.

You should have received training on the correct techniques to reconstitute and dilute Yondelis and you should wear protective clothing including mask, goggles and gloves during the reconstitution and
dilution. Accidental contact with the skin, eyes or mucous membranes must be treated immediately with copious amounts of water. You should not work with this medicine if you are pregnant.

Preparation for intravenous infusion:

Yondelis must be reconstituted and further diluted prior to infusion (see also section 3). *Appropriate aseptic techniques must be used.*

Yondelis must not be administered as a mixture with other medicines in the same infusion apart from the diluent. No incompatibilities have been observed between Yondelis and polyvinylchloride (PVC) and polyethylene (PE) bags and tubing, and titanium implantable vascular access systems.

*Instructions for reconstitution:*

*Yondelis 0.25 mg:* Inject 5 ml of sterile water for injections into the vial.

*Yondelis 1 mg:* Inject 20 ml of sterile water for injections into the vial.

A syringe is used to inject the correct amount of sterile water for injections into the vial. Shake the vial until complete dissolution. The reconstituted solution results in a clear, colourless or slightly yellowish solution, essentially free of visible particles.

This reconstituted solution contains 0.05 mg/ml of trabectedin. It requires further dilution and is for single-use only.

*Instructions for dilution:*

Dilute the reconstituted solution with sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose 50 mg/ml (5%) solution for infusion. Calculate the required volume as follows:

\[
\text{Volume (ml)} = \frac{\text{BSA (m}^2\text{)} \times \text{individual dose (mg/m}^2\text{)}}{0.05 \text{ mg/ml}}
\]

BSA = Body Surface Area

Withdraw the appropriate amount of solution from the vial. If administration is to be made via a central venous line, add the reconstituted solution to an infusion bag containing ≥ 500 ml of diluent (sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose 50 mg/ml (5%) solution for infusion).

If central venous access is not feasible and a peripheral venous line has to be used, add the reconstituted solution to an infusion bag containing ≥ 1,000 ml of diluent (sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose 50 mg/ml (5%) solution for infusion).

Inspect the parenteral solution visually for particles prior to administration. Once the infusion is prepared, it should be administered immediately.

*In-use stability of the solutions:*

*Reconstituted solution:*

After reconstitution, chemical and physical stability has been demonstrated for 30 hours up to 25°C.

From a microbiological point of view, the reconstituted solution should be diluted and used immediately. If not diluted and used immediately, in-use storage times and conditions prior to use of the reconstituted solution are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless reconstitution has taken place in controlled and validated aseptic conditions.
*Diluted solution:*
After dilution, chemical and physical stability has been demonstrated for 30 hours up to 25°C.